American Journal of BioMedicine Volume 2, Issue 12, pages1229-1239 December 2014
Bassim I Mohammad; Nada Al-Haris; Najah Hadi; Maitham G. Yousif; Zainab Alkefaee
Doxorubicin (Dox) is one of the most potent broad-spectrum antitumor anthracycline antibiotics, but its use is limited by the development of life-threatening cardiomyopathy. This study was undertaken to investigate the cardioprotective effect of ferulic acid and syringic acid on doxorubicin induced cardiotoxicity. The rats were randomized into 4 equal groups, Group 1 sham group, which received no treatment, group 2, received doxorubicin at a dose 3mg/Kg IP every other 2 days plus normal saline as vehicle orally and considered as Cardiotoxic group (DOX), group 3 received doxorubicin plus ferulic acid 10mg/kg/day p.o for 2 weeks. Group 4 received doxorubicin plus syringic acid 100mg/kg/day p.o for 2 weeks. Compared with the sham group, levels of myocardial TNF-α, IL-1βand IL-10; plasma cTn-I were increased (P<0.001), Doxorubicin treatment also increased MDA, hs-CRP level and lead to impairment of left ventricular function, expressed as a significant increase in both end-diastolic and systolic volume (LVEDV, LVESV) as well as a significant reduction (P<0.001) in both end diastolic and systolic pressure (LVEDP, LVESP) ,cardiac output (CO) and left ventricular ejection fraction (LVEF) values compared to sham group. All these were counteracted by administration of ferulic acid and syringic acid. The results of the present study reveal that these two phenolic compounds have a promising cardioprotective effect against doxorubicin-induced cardiotoxicity.
Keywords: Doxorubicin; Cardiotoxicty; Inflammatory response; Left ventricular function; Ferulic acid; Syringic acid.
Open Access Full Text-PDF Feedback